Although its second fund is considerably larger than its first, Novo Tellus Capital Partners expects to target the same kind of Southeast Asian industrial technology businesses that have succession and expansion issues
Southeast Asia private equity is not the easiest sell. LPs generally cite uninspiring performance and a shallow pool of investable managers as reasons for their wariness. This could be linked to difficulties...
SciClone Pharmaceuticals, a Chinese drug developer privatized by a PE consortium at a valuation of $605 million in 2017, has relisted in Hong Kong and ended its first day of trading with a market capitalization of HK$12.7 billion ($1.64 billion).
Iluvatar CoreX, a Shanghai-based computing chip designer has raised RMB1.2 billion ($186 million) in Series C funding led by Cedarlake Capital and Centurium Capital.
China’s less-than-truckload logistics market, which sits in between express couriers and big truck operators, is ripe for consolidation. GPs have identified their favored players
US-based Platinum Equity has exited its control position in Sensis, best known as the operator of Australia’s White Pages and Yellow Pages directories, in a deal worth $200 million.